<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://peptidesagora.com/news/bryan-johnson-dog-wolverine-stack-veterinary</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Bryan Johnson's Dog Post Puts 'Wolverine Stack' Peptides Under Veterinary Scrutiny]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/bryan-johnson-dog-wolverine-stack-veterinary.jpg</image:loc>
      <image:title><![CDATA[Bryan Johnson's Dog Post Puts 'Wolverine Stack' Peptides Under Veterinary Scrutiny]]></image:title>
      <image:caption><![CDATA[Bryan Johnson's September 12 X post referencing the BPC-157 and TB-500 'Wolverine Stack' for his dog arrived six weeks after an FDA advisory panel recommended the peptides for human compounding, a designation that does not extend to.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-panel-backs-6-peptides-compounding</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Advisory Panel Overrides Staff Scientists to Back Six Peptides for 503A Compounding]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-panel-backs-6-peptides-compounding.jpg</image:loc>
      <image:title><![CDATA[FDA Advisory Panel Overrides Staff Scientists to Back Six Peptides for 503A Compounding]]></image:title>
      <image:caption><![CDATA[A reconstituted advisory panel voted against FDA staff recommendations on six of seven peptides, opening a rulemaking path for compounds with no completed Phase 3 trials.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-peptide-reversal-glp-1-compounding-divide</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Panel Backs 6 Compounded Peptides as Agency Moves to Exclude GLP-1s]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-peptide-reversal-glp-1-compounding-divide.jpg</image:loc>
      <image:title><![CDATA[FDA Panel Backs 6 Compounded Peptides as Agency Moves to Exclude GLP-1s]]></image:title>
      <image:caption><![CDATA[In a regulatory divergence with few precedents, the FDA's Pharmacy Compounding Advisory Committee backed BPC-157 and five other peptides for compounding eligibility despite internal scientific dissent, even as the agency moved to.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-split-verdict-peptides-glp1-compounding</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Splits Peptide Path: Panel Backs BPC-157 as GLP-1 Compounding Faces Ban]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-split-verdict-peptides-glp1-compounding.jpg</image:loc>
      <image:title><![CDATA[FDA Splits Peptide Path: Panel Backs BPC-157 as GLP-1 Compounding Faces Ban]]></image:title>
      <image:caption><![CDATA[The FDA's Pharmacy Compounding Advisory Committee narrowly backed BPC-157, TB-500, and four other peptides for small-scale compounding, even as the agency proposed a permanent exclusion of semaglutide and tirzepatide from large-scale.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/lilly-retatrutide-black-market-lawsuits</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Lilly's Six Lawsuits Target Black-Market Sellers of Unapproved Retatrutide]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/lilly-retatrutide-black-market-lawsuits.jpg</image:loc>
      <image:title><![CDATA[Lilly's Six Lawsuits Target Black-Market Sellers of Unapproved Retatrutide]]></image:title>
      <image:caption><![CDATA[By suing compounding pharmacies, medical spas, and online peptide sellers before retatrutide reaches a pharmacy shelf, Eli Lilly is asking federal courts to enforce a market boundary that does not yet exist in law.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/mounjaro-cardiovascular-indication-approval</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Expands Mounjaro Label to Reduce Heart Attack and Stroke Risk in Type 2 Diabetes]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/mounjaro-cardiovascular-indication-approval.jpg</image:loc>
      <image:title><![CDATA[FDA Expands Mounjaro Label to Reduce Heart Attack and Stroke Risk in Type 2 Diabetes]]></image:title>
      <image:caption><![CDATA[Eli Lilly's dual GIP/GLP-1 agonist Mounjaro received FDA authorization to reduce cardiovascular death, heart attack, and stroke risk in adults with type 2 diabetes, matching Novo Nordisk's earlier Ozempic indication through a different.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/oral-glp1-phase-3-12-weight-loss</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Ascletis Doses First Patient in 4,600-Person Oral GLP-1 Phase 3 Program]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/oral-glp1-phase-3-12-weight-loss.jpg</image:loc>
      <image:title><![CDATA[Ascletis Doses First Patient in 4,600-Person Oral GLP-1 Phase 3 Program]]></image:title>
      <image:caption><![CDATA[The first participant received ASC30 in Ascletis' global Phase 3 program on August 30, 2026. The AURORA trials will enroll approximately 4,600 adults across the U.S. and Europe, though no interim efficacy data has been reported. The.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/tiktok-teens-unregulated-peptides-danger</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[TikTok Looksmaxxing Is Pushing Teens to Inject Unregulated Peptides]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/tiktok-teens-unregulated-peptides-danger.jpg</image:loc>
      <image:title><![CDATA[TikTok Looksmaxxing Is Pushing Teens to Inject Unregulated Peptides]]></image:title>
      <image:caption><![CDATA[Teens are self-injecting peptides sold online as 'for research use only,' following tutorials on TikTok. FDA reviewers found the human safety data barely exists, and no agency has closed the regulatory gap that lets vendors ship unverified.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/veterinary-wolverine-stack-mainstream</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-31T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Viral 'Wolverine Stack' Videos Push Unapproved Peptides Into Dog Care Without Safety Data]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/veterinary-wolverine-stack-mainstream.jpg</image:loc>
      <image:title><![CDATA[Viral 'Wolverine Stack' Videos Push Unapproved Peptides Into Dog Care Without Safety Data]]></image:title>
      <image:caption><![CDATA[An eleven-year-old dog's mobility video went viral in August 2026, accelerating interest in the unapproved BPC-157 and TB-500 combination for pets. Veterinary researchers warn the evidence base consists of rodent studies and a single.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-telehealth-glp1-marketing-warning-letters</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-28T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Slaps 30 Telehealth Firms with Warning Letters Over Compounded GLP-1 Marketing]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-telehealth-glp1-marketing-warning-letters.jpg</image:loc>
      <image:title><![CDATA[FDA Slaps 30 Telehealth Firms with Warning Letters Over Compounded GLP-1 Marketing]]></image:title>
      <image:caption><![CDATA[FDA Commissioner Marty Makary called it a new era of enforcement. Thirty telehealth companies received warning letters for marketing compounded GLP-1 drugs as equivalent to Ozempic and Mounjaro, with 15 business days to correct violations.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/samsung-biologics-polypeptide-acquisition-2-2b</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-28T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Samsung Biologics Approves $2.2B Rights Offering to Fund PolyPeptide Deal]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/samsung-biologics-polypeptide-acquisition-2-2b.jpg</image:loc>
      <image:title><![CDATA[Samsung Biologics Approves $2.2B Rights Offering to Fund PolyPeptide Deal]]></image:title>
      <image:caption><![CDATA[Samsung Biologics voted August 28 to raise 3 trillion won through a rights offering, dedicating most proceeds to its record PolyPeptide Group purchase and the rest to a sixth plant in Incheon. Shares fell on dilution concerns.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/samsung-biologics-polypeptide-acquisition-funding</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-28T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Samsung Biologics Prices $2.2B Rights Offering to Close PolyPeptide Acquisition]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/samsung-biologics-polypeptide-acquisition-funding.jpg</image:loc>
      <image:title><![CDATA[Samsung Biologics Prices $2.2B Rights Offering to Close PolyPeptide Acquisition]]></image:title>
      <image:caption><![CDATA[The Aug. 28 rights offering prices 2.27 million shares at 1.322 million won each, directing 2.71 trillion won to the Swiss CDMO deal and 294.8 billion won to Bio Campus II expansion.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/glutathione-iv-reactions-supplier-lot</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-27T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Trace of 30 IV Glutathione Reactions to Medisca Lot 229536 Exposes Compounding Gap]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/glutathione-iv-reactions-supplier-lot.jpg</image:loc>
      <image:title><![CDATA[FDA Trace of 30 IV Glutathione Reactions to Medisca Lot 229536 Exposes Compounding Gap]]></image:title>
      <image:caption><![CDATA[The FDA issued an alert on August 27 linking at least 30 severe patient reactions to Medisca Inc. Lot 229536. The ingredient carried a dietary-supplement label but was compounded into IV drips by multiple pharmacies, bypassing sterility.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/retatrutide-early-access-expansion</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-27T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Eli Lilly Expands 'Early Access' to Retatrutide as Black Market Pressure Builds]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/retatrutide-early-access-expansion.jpg</image:loc>
      <image:title><![CDATA[Eli Lilly Expands 'Early Access' to Retatrutide as Black Market Pressure Builds]]></image:title>
      <image:caption><![CDATA[Six weeks after a single 79-year-old patient received compassionate-use retatrutide, Eli Lilly confirmed a formal expanded access pathway on August 3 and filed six lawsuits against black-market sellers nine days later. The dual strategy.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/ai-venom-peptide-antibiotic-discovery</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-26T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[AI Screened 40 Million Venom Sequences to Find Next-Gen Antibiotics]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/ai-venom-peptide-antibiotic-discovery.jpg</image:loc>
      <image:title><![CDATA[AI Screened 40 Million Venom Sequences to Find Next-Gen Antibiotics]]></image:title>
      <image:caption><![CDATA[University of Pennsylvania researchers used the APEX model to scan 40.6 million venom-encrypted peptides and identified 386 candidates. Of the 58 peptides synthesized for bench testing, 53 killed drug-resistant bacteria without harming.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/cagrilintide-semaglutide-combo-phase-3-results</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-25T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[CagriSema Phase 3 Data Show 22.7% Mean Weight Loss, 60% Hit 20% Mark]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cagrilintide-semaglutide-combo-phase-3-results.jpg</image:loc>
      <image:title><![CDATA[CagriSema Phase 3 Data Show 22.7% Mean Weight Loss, 60% Hit 20% Mark]]></image:title>
      <image:caption><![CDATA[In a 3,417-patient Phase IIIa trial across 22 countries, Novo Nordisk's once-weekly CagriSema combination produced a 22.7% mean weight reduction and placed 60% of participants above the 20% loss threshold, exceeding semaglutide and.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/canine-biohacking-pet-peptide-therapy-trend</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-25T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Pet Owners Inject Dogs With 'Wolverine Stack' as FDA Panel Vote Fuels Uncertainty]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/canine-biohacking-pet-peptide-therapy-trend.jpg</image:loc>
      <image:title><![CDATA[Pet Owners Inject Dogs With 'Wolverine Stack' as FDA Panel Vote Fuels Uncertainty]]></image:title>
      <image:caption><![CDATA[The surge in social media posts showing aging dogs regaining mobility after BPC-157 injections has outpaced regulatory safeguards. While an FDA advisory panel recently voted to recommend six peptides for compounding, the agency maintains.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/australia-contaminated-peptide-liver-damage-alert</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-24T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Victoria's Seventh Liver Injury Fuels Contaminated-Batch Hypothesis]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/australia-contaminated-peptide-liver-damage-alert.jpg</image:loc>
      <image:title><![CDATA[Victoria's Seventh Liver Injury Fuels Contaminated-Batch Hypothesis]]></image:title>
      <image:caption><![CDATA[Seven Victorian patients hospitalized with acute liver toxicity after injecting counterfeit retatrutide have prompted doctors and the TGA to publicly raise a contaminated-batch hypothesis, though forensic testing has not yet identified the.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/australia-counterfeit-peptide-liver-toxicity-clusters</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-24T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Victorian Doctors Warn of 'Contaminated Batch' Linked to Seven Cases of Liver Failure]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/australia-counterfeit-peptide-liver-toxicity-clusters.jpg</image:loc>
      <image:title><![CDATA[Victorian Doctors Warn of 'Contaminated Batch' Linked to Seven Cases of Liver Failure]]></image:title>
      <image:caption><![CDATA[Liver transplant specialist Marie Sinclair reported a seventh Victorian patient with acute liver toxicity after injecting unapproved retatrutide. The TGA's Robyn Langham called the localized cluster a likely 'batch problem,' while Sinclair.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/counterfeit-peptide-batch-liver-damage-australia</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-24T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Seven Victorians Hospitalized as Doctors Link Counterfeit Peptide Batch to Liver Damage]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/counterfeit-peptide-batch-liver-damage-australia.jpg</image:loc>
      <image:title><![CDATA[Seven Victorians Hospitalized as Doctors Link Counterfeit Peptide Batch to Liver Damage]]></image:title>
      <image:caption><![CDATA[Liver transplant specialists in Melbourne are investigating a cluster of seven hospitalizations linked to counterfeit retatrutide. TGA officials suggest a localized 'batch problem' rather than inherent drug toxicity, highlighting the.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/counterfeit-peptide-batch-liver-toxicity-australia</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-24T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[TGA Flags 'Batch Problem' in Counterfeit Retatrutide Amid Seventh Victorian Liver Injury]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/counterfeit-peptide-batch-liver-toxicity-australia.jpg</image:loc>
      <image:title><![CDATA[TGA Flags 'Batch Problem' in Counterfeit Retatrutide Amid Seventh Victorian Liver Injury]]></image:title>
      <image:caption><![CDATA[The Therapeutic Goods Administration has identified a 'localised' cluster of liver injuries in Victoria linked to counterfeit retatrutide. As the seventh patient is hospitalized, officials warn that unapproved products sold online bypass.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-panel-grifters-backlash-rfk-peptide-push</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-24T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Panel's 'Grifters' Accusation: The Backlash Against RFK Jr.'s Peptide Push]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-panel-grifters-backlash-rfk-peptide-push.jpg</image:loc>
      <image:title><![CDATA[FDA Panel's 'Grifters' Accusation: The Backlash Against RFK Jr.'s Peptide Push]]></image:title>
      <image:caption><![CDATA[The FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, TB-500, and four other peptides for the 503A Bulks List, overriding internal safety concerns. Critics now argue the panel's composition reflects political.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/rfk-jr-fda-panel-grifters-peptide-vote</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-24T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[The 'Grifter' Panel: RFK Jr.'s FDA Advisers Override Science on BPC-157 and TB-500]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/rfk-jr-fda-panel-grifters-peptide-vote.jpg</image:loc>
      <image:title><![CDATA[The 'Grifter' Panel: RFK Jr.'s FDA Advisers Override Science on BPC-157 and TB-500]]></image:title>
      <image:caption><![CDATA[The FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, TB-500, and four other peptides for the 503A Bulks List, overriding career scientists who cited insufficient safety data. A new viewpoint labels the panel.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/victoria-contaminated-peptide-batch-liver-toxicity</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-24T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Victoria's Seventh Liver-Toxicity Case Linked to Contaminated Peptide Batch]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/victoria-contaminated-peptide-batch-liver-toxicity.jpg</image:loc>
      <image:title><![CDATA[Victoria's Seventh Liver-Toxicity Case Linked to Contaminated Peptide Batch]]></image:title>
      <image:caption><![CDATA[Liver transplant specialist Dr Marie Sinclair confirmed the seventh case of acute liver injury linked to unapproved retatrutide in Victoria, raising the possibility that a contaminated counterfeit batch is circulating. The TGA calls it a.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/cagrilintide-semaglutide-combo-trial-results</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-23T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[REDEFINE 1: Cagrilintide–Semaglutide Combo Delivers 20%+ Weight Loss in 60% of Patients]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cagrilintide-semaglutide-combo-trial-results.jpg</image:loc>
      <image:title><![CDATA[REDEFINE 1: Cagrilintide–Semaglutide Combo Delivers 20%+ Weight Loss in 60% of Patients]]></image:title>
      <image:caption><![CDATA[In the REDEFINE 1 trial, Novo Nordisk's dual-mechanism injectable CagriSema delivered mean weight loss of 20.4% at 68 weeks, and 60% of adherent participants shed at least a fifth of their body weight, outpacing semaglutide or cagrilintide.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/cagrilintide-semaglutide-combo-trial-results-weight-loss</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-23T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Cagrilintide-Semaglutide Combo Achieves 20%+ Weight Loss in REDEFINE 1 Trial]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/cagrilintide-semaglutide-combo-trial-results-weight-loss.jpg</image:loc>
      <image:title><![CDATA[Cagrilintide-Semaglutide Combo Achieves 20%+ Weight Loss in REDEFINE 1 Trial]]></image:title>
      <image:caption><![CDATA[Sixty percent of REDEFINE 1 participants achieved 20% or greater body-weight reduction on the cagrilintide-semaglutide combination, a threshold previously linked to bariatric surgery. The drug has no FDA approval, no published price, and.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/glutathione-recall-bacterial-toxin-2026</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-23T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Second Texas Pharmacy Recalls Glutathione Amid 'Deadly' Bacterial Toxin Alarms]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/glutathione-recall-bacterial-toxin-2026.jpg</image:loc>
      <image:title><![CDATA[Second Texas Pharmacy Recalls Glutathione Amid 'Deadly' Bacterial Toxin Alarms]]></image:title>
      <image:caption><![CDATA[Houston-based Optimal Balance Pharmacy recalled lot LG342009076 of compounded glutathione on August 19, 2026, after pharmacy testing found elevated bacterial endotoxin levels. The FDA published the notice August 20. Two weeks earlier.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-30-warning-letters-telehealth-peptides</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-22T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA's 30 Warning Letters: The 'Telehealth Peptide' Crackdown Begins in Earnest]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-30-warning-letters-telehealth-peptides.jpg</image:loc>
      <image:title><![CDATA[FDA's 30 Warning Letters: The 'Telehealth Peptide' Crackdown Begins in Earnest]]></image:title>
      <image:caption><![CDATA[Thirty telehealth firms received FDA warning letters for implying compounded GLP-1 products were interchangeable with Wegovy and Zepbound. The letters carry a 15-day compliance deadline and threats of seizure.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/pet-peptide-boom-bpc-157-dog-owners</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-22T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Dog Owners Inject BPC-157 and TB-500 as FDA Compounding Vote Fuels a Pet Peptide Surge]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/pet-peptide-boom-bpc-157-dog-owners.jpg</image:loc>
      <image:title><![CDATA[Dog Owners Inject BPC-157 and TB-500 as FDA Compounding Vote Fuels a Pet Peptide Surge]]></image:title>
      <image:caption><![CDATA[After the FDA advisory panel's July 2026 vote on compounding access, dog owners are administering BPC-157 and TB-500 using dosing figures drawn from informal sources. No canine clinical trial supports the practice, and no veterinary.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/veterinary-wolverine-stack-trend</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-22T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Viral Dog-Peptide Videos Outpace Veterinary Safety Data After FDA Vote]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/veterinary-wolverine-stack-trend.jpg</image:loc>
      <image:title><![CDATA[Viral Dog-Peptide Videos Outpace Veterinary Safety Data After FDA Vote]]></image:title>
      <image:caption><![CDATA[Pet owners are injecting aging dogs with BPC-157 after viral mobility videos, while veterinary clinicians warn no published trial establishes a safe canine dose. The FDA's July advisory vote addressed human compounding only.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/rogan-damon-wolverine-stack-doping-ban</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-20T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[USADA Bans Weightlifter as 'Wolverine Stack' Celebrity Hype Collides with Doping Rules]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/rogan-damon-wolverine-stack-doping-ban.jpg</image:loc>
      <image:title><![CDATA[USADA Bans Weightlifter as 'Wolverine Stack' Celebrity Hype Collides with Doping Rules]]></image:title>
      <image:caption><![CDATA[Weightlifter Jara MacDermott accepted a two-year ineligibility on August 20, 2026, for testing positive for canrenone, amphetamine, and testosterone. The sanction landed eight days after USADA publicly flagged BPC-157 as a banned peptide.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/usada-suspends-weightlifter-peptide-use</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-20T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[USADA Suspends Weightlifter for Peptide Use, Igniting 'Peptide Ban' Debate in Elite Sports]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/usada-suspends-weightlifter-peptide-use.jpg</image:loc>
      <image:title><![CDATA[USADA Suspends Weightlifter for Peptide Use, Igniting 'Peptide Ban' Debate in Elite Sports]]></image:title>
      <image:caption><![CDATA[Weightlifter Jara MacDermott accepted a two-year period of ineligibility on August 20, 2026, for testing positive for canrenone, amphetamine, and testosterone. The announcement arrives eight days after USADA publicly flagged BPC-157 as a.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/oral-wegovy-launch-impact-peptide-market</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-19T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Oral Wegovy's Launch Reshapes the Peptide Hierarchy: Injection vs. Pill]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/oral-wegovy-launch-impact-peptide-market.jpg</image:loc>
      <image:title><![CDATA[Oral Wegovy's Launch Reshapes the Peptide Hierarchy: Injection vs. Pill]]></image:title>
      <image:caption><![CDATA[The FDA cleared oral semaglutide 25 mg as the first GLP-1 pill for weight loss on December 22, 2025. Truveta data shows the pill drew thousands of new patients into GLP-1 therapy. Eli Lilly's orforglipron awaits FDA review.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/kailera-therapeutics-obesity-ipo-analysis</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-18T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Kailera's $625M IPO Leaves Big Pharma Deciding Between Licensing Ribupatide or Competing]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/kailera-therapeutics-obesity-ipo-analysis.jpg</image:loc>
      <image:title><![CDATA[Kailera's $625M IPO Leaves Big Pharma Deciding Between Licensing Ribupatide or Competing]]></image:title>
      <image:caption><![CDATA[Kailera Therapeutics closed at $18.51 on August 18, down 28.8% from its record-breaking April IPO. The Waltham biotech, spun out of Hengrui Pharma, holds $1.17 billion in cash and a dual GIP/GLP-1 agonist in global Phase 3.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/unregulated-mots-c-use-researchers-warn</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-18T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Researchers Warn of Unregulated MOTS-c Sales in 'Gym Rat' Community]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/unregulated-mots-c-use-researchers-warn.jpg</image:loc>
      <image:title><![CDATA[Researchers Warn of Unregulated MOTS-c Sales in 'Gym Rat' Community]]></image:title>
      <image:caption><![CDATA[The USC gerontologist who identified MOTS-c is sounding the alarm on a thriving online trade that sells the mouse-exercise peptide to consumers without purity or sterility guarantees.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/verlytix-peptide-testing-expansion</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-18T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Verlytix Launches Peptide QC Platform Tied to LyoGenesis Manufacturing]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/verlytix-peptide-testing-expansion.jpg</image:loc>
      <image:title><![CDATA[Verlytix Launches Peptide QC Platform Tied to LyoGenesis Manufacturing]]></image:title>
      <image:caption><![CDATA[The Mequon, Wis., contract lab announced an expanded quality analytical testing platform for peptides, with Vector Science & Therapeutics as its first named client under a LyoGenesis Holdings agreement.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/longevity-peptides-science-reality-check</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-17T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Advisory Vote Opens Compounding Path for Epitalon and MOTS-c, but Human Trials Are Sti]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/longevity-peptides-science-reality-check.jpg</image:loc>
      <image:title><![CDATA[FDA Advisory Vote Opens Compounding Path for Epitalon and MOTS-c, but Human Trials Are Sti]]></image:title>
      <image:caption><![CDATA[The FDA advisory panel voted to recommend compounding access for two longevity peptides, Epitalon and MOTS-c, while its own staff argued the evidence was insufficient. New expert reviews lay out how far the science remains from the.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/rfk-jr-peptide-politics-fda-science</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-17T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Advisory Panel Sides With Kennedy's Peptide Agenda Over Its Own Scientists' Warnings]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/rfk-jr-peptide-politics-fda-science.jpg</image:loc>
      <image:title><![CDATA[FDA Advisory Panel Sides With Kennedy's Peptide Agenda Over Its Own Scientists' Warnings]]></image:title>
      <image:caption><![CDATA[A narrowly composed FDA advisory panel recommended placing six unproven peptides into a category that permits pharmacy compounding, over the objections of career scientists. The vote follows HHS Secretary RFK Jr.'s personal advocacy and.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/aizen-ai-peptide-collaboration-100m</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-16T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Aizen Signs $100M AI Peptide Deal]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/aizen-ai-peptide-collaboration-100m.jpg</image:loc>
      <image:title><![CDATA[Aizen Signs $100M AI Peptide Deal]]></image:title>
      <image:caption><![CDATA[Aizen Therapeutics, a San Diego-based AI biotech spun out of Caltech, has entered a multi-program collaboration with an undisclosed public partner. The deal includes upfront funding and up to $100 million in milestone payments per target.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-panel-votes-six-peptides-category-1-compounding</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-15T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Staff Opposed All Seven Peptides. The Advisory Panel Overruled Them.]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-panel-votes-six-peptides-category-1-compounding.jpg</image:loc>
      <image:title><![CDATA[FDA Staff Opposed All Seven Peptides. The Advisory Panel Overruled Them.]]></image:title>
      <image:caption><![CDATA[FDA staff scientists recommended against every peptide under review. The advisory panel voted six through anyway, citing grey-market harm. Formal rulemaking now determines whether compounding pharmacies gain legal access.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/eli-lilly-lawsuits-illicit-peptide-market</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-12T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Eli Lilly Targets Illicit Market for Unapproved Weight-Loss Peptide]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/eli-lilly-lawsuits-illicit-peptide-market.jpg</image:loc>
      <image:title><![CDATA[Eli Lilly Targets Illicit Market for Unapproved Weight-Loss Peptide]]></image:title>
      <image:caption><![CDATA[The drugmaker is suing four online peptide sellers, a California med spa, and a compounding pharmacy for marketing an unapproved triple-receptor agonist to consumers under a 'research use' label.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/eli-lilly-retatrutide-black-market-lawsuits</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-12T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Eli Lilly Files Six Federal Lawsuits to Dismantle the Retatrutide 'Research-Use Only' Mark]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/eli-lilly-retatrutide-black-market-lawsuits.jpg</image:loc>
      <image:title><![CDATA[Eli Lilly Files Six Federal Lawsuits to Dismantle the Retatrutide 'Research-Use Only' Mark]]></image:title>
      <image:caption><![CDATA[Eli Lilly filed six federal lawsuits against compounding pharmacies, med spas, and online sellers marketing unapproved retatrutide as 'research-use only,' challenging a labeling convention the drugmaker says conceals illegal human.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/eli-lilly-retatrutide-lawsuit-enforcement</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-12T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Eli Lilly Sues Six Retatrutide Sellers, Escalating Beyond Agency Referrals]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/eli-lilly-retatrutide-lawsuit-enforcement.jpg</image:loc>
      <image:title><![CDATA[Eli Lilly Sues Six Retatrutide Sellers, Escalating Beyond Agency Referrals]]></image:title>
      <image:caption><![CDATA[On August 12, 2026, Eli Lilly sued Aesthetic Envy, Astra, and four other entities over alleged illegal sales of its investigational obesity drug retatrutide. The company has referred over 200 entities to regulators and flagged 14,000.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/eli-lilly-sues-retatrutide-black-market-sellers</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-12T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Eli Lilly Sues Six Sellers Over Unapproved Retatrutide Sales]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/eli-lilly-sues-retatrutide-black-market-sellers.jpg</image:loc>
      <image:title><![CDATA[Eli Lilly Sues Six Sellers Over Unapproved Retatrutide Sales]]></image:title>
      <image:caption><![CDATA[Eli Lilly filed six federal lawsuits on August 12, 2026, against Aesthetic Envy, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide. The complaints allege these businesses sold illegal versions of.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/fda-panel-vote-implications-grey-market-peptides</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-11T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Panel's Narrow Vote Leaves BPC-157 and Semax in Regulatory Limbo]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-panel-vote-implications-grey-market-peptides.jpg</image:loc>
      <image:title><![CDATA[FDA Panel's Narrow Vote Leaves BPC-157 and Semax in Regulatory Limbo]]></image:title>
      <image:caption><![CDATA[The PCAC's July 23–24 votes to recommend BPC-157, Semax, and four other peptides for compounding eligibility override FDA scientists' unanimous opposition. Legal access still requires a rulemaking process with no set timeline.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/aleniglipron-oral-glp1-12-weight-loss</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Aleniglipron Posts 12.1% Weight Loss in Phase 2b Trial, Testing the GLP-1 Access Gap]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/aleniglipron-oral-glp1-12-weight-loss.jpg</image:loc>
      <image:title><![CDATA[Aleniglipron Posts 12.1% Weight Loss in Phase 2b Trial, Testing the GLP-1 Access Gap]]></image:title>
      <image:caption><![CDATA[A once-daily tablet from Structure Therapeutics achieved weight loss comparable to injectable semaglutide in a randomized trial, but the 230-person, U.S.-only Phase 2b design leaves open whether the access benefits of a small-molecule.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/stanford-experts-peptide-evidence-reality-check</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Stanford Pathologists Say Popular Peptide Injections Lack a Single Controlled Human Trial]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/stanford-experts-peptide-evidence-reality-check.jpg</image:loc>
      <image:title><![CDATA[Stanford Pathologists Say Popular Peptide Injections Lack a Single Controlled Human Trial]]></image:title>
      <image:caption><![CDATA[Two Stanford pathologists published an evidence review on August 12 separating FDA-approved peptide drugs from the unapproved compounds trending on social media, warning that most popular injectables have never entered a controlled human.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/canine-biohacking-peptide-mobility-recovery</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-08T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Viral 'Wolverine' Peptide Videos for Dogs Draw Veterinary Warnings Amid Regulatory Vacuum]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/canine-biohacking-peptide-mobility-recovery.jpg</image:loc>
      <image:title><![CDATA[Viral 'Wolverine' Peptide Videos for Dogs Draw Veterinary Warnings Amid Regulatory Vacuum]]></image:title>
      <image:caption><![CDATA[An 11-year-old dog's mobility transformation in a viral video has pet owners reaching for the same BPC-157 and TB-500 combination that biohackers call the Wolverine Stack. Veterinary professionals say no peer-reviewed trial supports the.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/celebrity-influencer-peptide-boom</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-08T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Panel Endorses Peptides Promoted by Rogan and RFK Jr., Bending Regulation Toward Podca]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/celebrity-influencer-peptide-boom.jpg</image:loc>
      <image:title><![CDATA[FDA Panel Endorses Peptides Promoted by Rogan and RFK Jr., Bending Regulation Toward Podca]]></image:title>
      <image:caption><![CDATA[The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23 to recommend placing BPC-157, TB-500, and other peptides on the agency's bulks list, a shift that follows years of promotion by Joe Rogan, RFK Jr., and wellness clinic.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/dog-peptide-therapy-bpc-157-trend</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-08T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Canine Biohacking: Inside the 'Wolverine Stack' Trend for Aging Dogs]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/dog-peptide-therapy-bpc-157-trend.jpg</image:loc>
      <image:title><![CDATA[Canine Biohacking: Inside the 'Wolverine Stack' Trend for Aging Dogs]]></image:title>
      <image:caption><![CDATA[The July 23 PCAC vote recommended six peptides for human compounding despite career scientists citing absent safety data. The decision amplified demand across informal markets, including pet-care channels where no dosing evidence exists.]]></image:caption>
    </image:image>
  </url>
</urlset>